Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

83.8 1.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

83.73

Max

84.58

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.81% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

16B

Vorige openingsprijs

82.53

Vorige sluitingsprijs

83.8

Nieuwssentiment

By Acuity

33%

67%

83 / 340 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 23:51 UTC

News

Tenet Healthcare reported second-quarter earnings of $6.12 per share, exceeding estimates. Shares are trading higher in after-market hours following the strong results.

24 jul 2026, 23:46 UTC

News

HF Sinclair Corp has filed a lawsuit against the EPA over biofuel blending delays. Shares rose during after-market hours, maintaining a strong monthly performance.

24 jul 2026, 23:41 UTC

News

Kinsale Capital Group reported Q2 earnings of $5.54 per share, exceeding estimates, with revenue of $548.5 million, driving shares higher in after-market trading.

24 jul 2026, 23:41 UTC

Macro News
ETF Constituents
News

The Vanguard Information Technology ETF is higher in after-market hours, supported by key holdings like Apple and Qualcomm, despite broader market declines.

24 jul 2026, 23:41 UTC

News

Datadog Inc. is higher in after-market trading, benefiting from steady quarter-over-quarter revenue growth despite being surpassed by CoreWeave in total revenue.

24 jul 2026, 23:41 UTC

News

Boeing Co shares advanced in after-market hours, supported by a $695 billion backlog and positive analyst outlook on growth potential.

24 jul 2026, 23:36 UTC

News

KKR & Co Inc shares are lower in after-market hours following a $238.954 million share sale, reflecting potential liquidity concerns and capital allocation shifts.

24 jul 2026, 23:31 UTC

News

Interactive Brokers Group reported a 77% pre-tax profit margin but shares are lower in after-market hours amid concerns over rising interest rates and profitability.

24 jul 2026, 23:21 UTC

News
Social Media

Micron Technology Inc shares are declining in after-market trading amid concerns over potential pricing pressures in the cyclical memory chip market.

24 jul 2026, 23:21 UTC

Social Media
News

Warner Bros Discovery shares are lower in after-market trading as merger plans with Paramount Skydance are postponed until June 2027 amid legal challenges.

24 jul 2026, 23:21 UTC

News

Baker Hughes Co shares rose in after-market hours after a decrease in the active rig count, which fell to 587, the lowest since mid-July.

24 jul 2026, 23:16 UTC

News

CS PowerTech has launched its photovoltaic cell facility in Indiana, boosting Canadian Solar's U.S. manufacturing capabilities. Shares are higher in after-market trading.

24 jul 2026, 23:16 UTC

News

Liberty Energy reported Q2 revenue of $1.19 billion, exceeding estimates. Shares are higher in after-market trading following the earnings release.

24 jul 2026, 23:06 UTC

News

American Airlines Group Inc shares are lower in after-market hours following weaker profit guidance for the third quarter amid rising fuel costs.

24 jul 2026, 23:01 UTC

ETF Constituents
News

Vanguard Growth ETF advances in after-market trading, supported by contributions from Apple, Uber, and Applied Materials, following three lower daily closes.

24 jul 2026, 23:01 UTC

News

Elme Communities announced property sales totaling $294 million and revised liquidating distributions to $16.41 to $16.61 per share, trading higher in after-market hours.

24 jul 2026, 23:01 UTC

News

CACI International Inc. shares declined in after-market trading, influenced by a downturn in the Research & Consulting Services sub-sector.

24 jul 2026, 23:01 UTC

News

Emerson Electric Co shares are lower in after-market trading amid mixed market sentiment influenced by geopolitical tensions and new tariffs from the Trump administration.

24 jul 2026, 23:01 UTC

News

Carrier Global Corp shares declined in after-market hours following the appointment of PTC's Neil Barua to its board, effective immediately.

24 jul 2026, 23:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

24 jul 2026, 22:22 UTC

News
Social Media

Uber shares are higher in after-market hours amid intensifying discussions about its partnership with Waymo and potential regulatory moves in the autonomous vehicle sector.

24 jul 2026, 22:02 UTC

News

ServiceNow shares are lower in after-market trading despite reporting $4 billion in revenue and raising full-year subscription guidance amid ongoing sector concerns.

24 jul 2026, 22:01 UTC

News
Social Media

Booz Allen Hamilton reported Q1 fiscal 2027 adjusted EPS of $1.81, exceeding expectations, and provided optimistic revenue guidance, boosting shares higher in after-market hours.

24 jul 2026, 21:41 UTC

News

Tractor Supply Co shares are lower in after-market hours, continuing a decline amid broader market volatility linked to geopolitical tensions and oil supply concerns.

24 jul 2026, 21:31 UTC

News

Embecta Corp is facing a securities class action lawsuit for allegedly misleading investors about its fiscal results, contributing to lower after-market hours trading.

24 jul 2026, 21:01 UTC

News

Golub Capital Bdc Inc reported a net asset value of $4.5 billion and is conducting a public offering of up to $10 billion in shares.

24 jul 2026, 21:01 UTC

News

Hercules Capital Inc's shares are lower after the company closed a $325 million note offering, with proceeds for debt repayment and investments.

24 jul 2026, 21:01 UTC

News

MetroCity Bankshares reported second-quarter net income of $22.1 million, missing expectations. Shares are higher in after-market trading, continuing a recent upward trend.

24 jul 2026, 20:07 UTC

Social Media
Correlated Moves
News

iShares Core U.S. Aggregate Bond ETF is gaining as major indices rebound amid lower crude oil prices and inflation concerns. The ETF's yield is 4.99%.

24 jul 2026, 20:07 UTC

News
Correlated Moves

Lovesac Co shares are lower as analysts express skepticism, citing slow revenue growth and weak free cash flow margins. The consensus price target is $24.17.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

27.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.39 USD  27.81%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

83 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat